Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

What the Study Claims and How Strongly the Data Support It

Using TCGA reverse phase protein array (RPPA) data, the authors trained an elastic-net penalized Cox model (glmnet, α = 0.5) on 102 primary untreated GBMs, selecting 13 proteins, and locked the β coefficients to score an independent 101-patient validation set. High-risk patients had markedly shorter median survival: 22.2 vs 12.0 months (training, p < 0.0001) and 16.9 vs 10.6 months (validation, p = 0.0009), with C-indices of 0.63 and 0.60. PROTGLIO remained significant in multivariable Cox models (p = 0.008 in both sets) alongside age, KPS, resection extent, TMZ, and MGMT methylation PROTGLIO survival performance and multivariable independence.

TGM2 carries the largest positive coefficient (0.54, higher abundance = higher risk); total Src and p-Src are protective (β = -0.20 and -0.17). Cox-2 and ANXA1 appeared in 9/10 repeated model-generation runs, with IGFBP2, p-CHEK1, and TGM2 in 7/10, and functional enrichment pointed to inflammatory/immune response pathways Robustness repetitions and inflammatory enrichment findings.

Validation Caveats

The LGG corroboration is indirect: a separate 12-protein IDHwt model (42 patients, only 21 per split) shared five proteins (AMPK1, ANXA1, CHEK1, IGFBP2, SRC) with the GBM model, but Cox-2 was not measured on the LGG array, so the PROTGLIO signature itself could not be computationally re-validated Incomplete LGG validation due to antibody panel mismatch. Critically, the 'validation' set is a random split of the same 203 TCGA tumors—not a fully external cohort—and repeated 2-fold CV yielded 37 different significant proteins across runs, so the exact 13-protein composition is unstable even if the score's predictive direction is reproducible. GCIMP/IDH1 could not enter the multivariable model for lack of degrees of freedom. The authors themselves call for retrospective and prospective proteomics studies before clinical use.

Confidence: moderate—the internal validation is statistically solid and the biology is plausible, but single-cohort dependence, signature instability across resampling, modest C-indices (~0.6), and no true external replication temper clinical translation claims.

 BGPT Paper Review

Study Novelty

First systematic linkage of TCGA GBM RPPA data to patient survival was reasonably new in 2016; the elastic-net Cox survival-signature approach itself was established (analogous ovarian work cited).

Scientific Quality

Sound statistical pipeline (elastic-net Cox, 10x repeated 2-fold CV, multivariable adjustment), but 'validation' is an internal random split of one cohort, the 13-protein composition is unstable across resampling runs, C-indices are modest (0.60-0.63), and IDH1/GCIMP covariates were excluded for insufficient degrees of freedom.

Study Generality

The signature is GBM-specific and was only partially corroborated in IDHwt LGGs, but the finding that inflammatory-response proteins (Cox-2, ANXA1) predict survival may generalize across cancers.

Study Usefulness

Provides a clinically actionable stratification concept using measurable protein abundance (IHC-feasible) and nominates Cox-2/ANXA1-inflammatory axes as therapeutic leads, though prospective validation is absent.

Study Reproducibility

Level-3 TCGA RPPA data are publicly available and the glmnet/R methods are precisely specified, but no public independent GBM RPPA dataset exists for direct external replication and exact signatures vary by resampling run.

Explanatory Depth

The paper is primarily predictive/statistical; mechanistic claims about Cox-2 and ANXA1 rest on prior literature rather than functional experiments, and pathway enrichment is descriptive.